Psychiatry Research
Volume 120, Issue 1 , Pages 13-27 , 30 August 2003

Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol

  • Leanne M. Williams

      Affiliations

    • School of Psychology, University of Sydney, Sydney, NSW 2006, Australia
    • The Brain Dynamics Centre, Westmead Hospital, Westmead, NSW 2145, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61-2-9845-6688; fax: +61-2-9845-7734
    • ,
  • Carmel M. Loughland

      Affiliations

    • School of Psychology, University of Sydney, Sydney, NSW 2006, Australia
    • Neuroscience Institute of Schizophrenia and Allied Disorders (NISAD), Centre for Mental Health Studies, University of Newcastle, Newcastle, Australia
    • ,
  • Melissa J. Green

      Affiliations

    • School of Psychology, University of Sydney, Sydney, NSW 2006, Australia
    • ,
  • Anthony W.F. Harris

      Affiliations

    • The Brain Dynamics Centre, Westmead Hospital, Westmead, NSW 2145, Australia
    • Department of Psychological Medicine, University of Sydney, Sydney, NSW 2006, Australia
    • ,
  • Evian Gordon

      Affiliations

    • The Brain Dynamics Centre, Westmead Hospital, Westmead, NSW 2145, Australia
    • Department of Psychological Medicine, University of Sydney, Sydney, NSW 2006, Australia

Received 26 July 2002 ,Revised 3 April 2003 ,Accepted 13 June 2003.

References 

  1. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: Author; 1994;
  2. Amado-Boccara I, Galinowski A, Poirier MF, Loo H. Effect of psychotropic drugs on vigilance and motor performances. Presse Medicale. 1992;21:899–902
  3. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1981;
  4. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa; 1984;
  5. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry. 2002;159(6):1018–1028
  6. Boon-Yasidhi V, Tarugsa J, Suwanwattana C, Soising L. Risperidone in the treatment of autistic Thai children under 4 years of age. Journal of the Medical Association of Thailand. 2002;85(Suppl 2):S784–789
  7. Borkowska A, Araszkiewicz A, Rajewski A, Rybakowski JK. Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests. Neuropsychobiology. 2002;46:85–89
  8. Borod JC, Martin CC, Alpert M, Brozgold A, Welkowitz J. Perception of facial emotion in schizophrenics and right brain-damaged patients. Journal of Nervous and Mental Disease. 1993;181:494–502
  9. Bryson G, Bell M, Lysaker P. Affect recognition in schizophrenia: a function of global impairment or a specific cognitive deficit. Psychiatry Research. 1997;71:105–113
  10. Burke JG, Reveley MA. Improved antisaccade performance with risperidone in schizophrenia. Journal of Neurology, Neurosurgery and Psychiatry. 2002;72:449–454
  11. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatrica Scandinavica. 1992;85:295–305
  12. Corbett R, Hartman H, Kerman LL, Woods AT, Strupczewski JT, Helsley GC, et al. Effects of atypical antipsychotic agents on social behaviour in rodents. Pharmacology and Biochemical Behavior. 1993;45:9–17
  13. Cramer P, Bowen J, O'Neill M. Schizophrenics and social judgement. Why do schizophrenics get it wrong?. British Journal of Psychiatry. 1992;160:481–487
  14. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophrenia Research. 2001;48:17–28
  15. David AS. Perceptual asymmetry for happy–sad chimeric faces: effects of mood. Neuropsychologia. 1989;27:1289–1300
  16. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research. 1987;22:303–310
  17. Feinberg TE, Rifkin A, Schaffer C, Walker E. Facial discrimination and emotional recognition in schizophrenia and affective disorders. Archives of General Psychiatry. 1986;43:276–279
  18. Gaebel W, Wolwer . Facial expression and emotional face recognition in schizophrenia and depression. European Archives of Psychiatry and Clinical Neuroscience. 1992;242:46–52
  19. Gordon E, Coyle S, Anderson J, Healey P, Cordaro J, Latimer C, et al. Eye movement response to a facial stimulus in schizophrenia. Biological Psychiatry. 1992;31:626–629
  20. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. American Journal of Psychiatry. 1997;154:799–804
  21. Green MJ, Williams LM, Davidson DJ. Processing of threat related affect is delayed in delusion-prone individuals. British Journal of Clinical Psychology. 2001;40:157–165
  22. Griffiths AN, Marshall RW, Richens A. Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance. British Journal of Clinical Pharmacology. 1984;18:73S–82S
  23. Harper RG, Wiens AN, Matarazzo JD. Nonverbal Communication: The State of Art. New York, NY: John Wiley; 1978;
  24. Horley K, Williams LM, Gonsalvez C, Gordon E. Social phobics do not see eye to eye: a visual scanpath study of emotional expression processing. Journal of Anxiety Disorders. 2003;17:33–44
  25. Just MA, Carpenter PA. The role of eye-fixation research in cognitive psychology. Behavior Research Methods, Instruments and Computers. 1976;8:139–143
  26. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS). North Tonawanda, NY: Multi-Health Systems Inc; 1986;
  27. Kee KS, Kern RS, Green MF. Perception of emotion and neurocognitive functioning in schizophrenia: what's the link?. Psychiatry Research. 1998;81:57–65
  28. Keppel G. Design and Analysis. A Researcher's Handbook. 2nd ed. Englewood Cliffs, NJ: Prentice-Hall; 1982;
  29. Kerr SL, Neale JM. Emotion perception in schizophrenia: specific deficit or further evidence of generalized poor performance?. Journal of Abnormal Psychology. 1993;102:312–318
  30. Kohler CG, Bilker W, Hagendoorn M, Gur RE, Gur RC. Emotion recognition deficit in schizophrenia: association with symptomatology and cognition. Biological Psychiatry. 2000;48:127–136
  31. Latimer CR. Eye-movement data: cumulative fixation time and cluster analysis. Behavior Research Methods, Instruments and Computers. 1998;20:437–470
  32. Loughland CM, Williams LM, Gordon E. Visual scanpaths and facial expressions of emotion in an outpatient schizophrenia sample. Schizophrenia Research. 2002;55:159–170
  33. Loughland CM, Williams LM, Gordon E. Schizophrenia and affective psychosis show different visual scanpath strategies for faces: a trait versus state-based distinction?. Biological Psychiatry. 2002;52:338–348
  34. Mandal MK, Pandey R, Prasad AB. Facial expressions of emotions and schizophrenia: a review. Schizophrenia Bulletin. 1998;24:399–412
  35. Manor B, Williams L, Gordon E, Rennie C, Bahramali H, Latimer C, et al. Eye movements in schizophrenics and non-psychiatric controls, processing geometric and neutral face stimuli. Biological Psychiatry. 1999;46:963–969
  36. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry. 1994;151:825–835
  37. Mazurski EJ, Bond NW. A new series of slides depicting facial expressions of affect: a comparison with the pictures of facial affect series. Australian Journal of Psychology. 1993;45:41–47
  38. Moritz S, Woodward TS, Krausz M, Naber D. Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. International Clinical Psychopharmacology. 2002;17:41–44
  39. Mueser KT, Doonan R, Penn DL, Blanchard JJ, Bellack AS, Nishith P, et al. Emotion recognition and social competence in chronic schizophrenia. Journal of Abnormal Psychology. 1996;105:271–275
  40. Mueser KT, Penn D, Blanchard JJ, Bellack AS. Affect recognition in schizophrenia: a synthesis of findings across three studies. Psychiatry. 1997;60:301–307
  41. Noton D, Stark I. Eye movements and visual perception. Scientific American. 1971;224:35–43
  42. Nyberg S, Farde L, Halldin C, Eriksson B. 5HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology. 1993;110:265–272
  43. Phillips ML, David AS. Visual scan paths are abnormal in deluded schizophrenics. Neuropsychologia. 1997;35:99–105
  44. Phillips ML, David AS. Abnormal visual scan paths: a psychophysiological marker of delusions in schizophrenia. Schizophrenia Research. 1998;29:235–245
  45. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, et al. The Composite International Diagnostic Interview. Archives of General Psychiatry. 1988;45:1069–1077
  46. Rosen AJ, Mueser KT, Sussman S, Davis JM. The effects of neuroleptic drugs on the social interaction of hospitalized psychotic patients. Journal of Nervous and Mental Disease. 1981;169:240–243
  47. Rybakowski JK, Borkowska A. The effect of treatment with risperidone, olanzapine or phenothiazines on cognitive functions in patients with schizophrenia. International Journal of Psychiatry in Clinical Practice. 2001;5:249–256
  48. Salokangas RK, Syvalanti E, Lentinen I. Dyskinesia and eye tracking dysfunction in young schizophrenia patients—a pilot study. Methods and findings in Experimental and Clinical Pharmacology. 1983;5(4):263–269
  49. Schneider F, Gur RC, Gur RE, Shtasel DL. Emotional processing in schizophrenia: neurobehavioural probes in relation to psychopathology. Schizophrenia Research. 1995;17:67–75
  50. Silver H, Shlomo N, Turner T, Gur RC. Perception of happy and sad facial expressions in chronic schizophrenia: evidence for two evaluative systems. Schizophrenia Research. 2002;55:171–177
  51. Streit M, Wolwer W, Gaebel W. Facial-affect recognition and visual scanning behaviour in the course of schizophrenia. Schizophrenia Research. 1997;24:311–317
  52. Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, et al. In vivo dopamine-D2 and serotonin 5-HT2 receptor binding study of risperidone and haloperidol. Pharmacology and Biochemical Behavior. 1994;47:553–557
  53. Sweeney JA, Bauer KS, Keshavan MS, Haas GL, Schooler NR, Kroboth PD. Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naı̈ve schizophrenic patients. Neuropsychopharmacology. 1997;16:217–228
  54. Walker E, McGuire M, Bettes B. Recognition and identification of facial stimuli by schizophrenics and patients with affective disorders. British Journal of Clinical Psychology. 1984;23:37–44
  55. Williams LM, Loughland CM, Gordon E, Davidson D. Visual scanpaths in schizophrenia: is there a deficit in face recognition?. Schizophrenia Research. 1999;40:189–199
  56. Zuroff DC, Colussy SA. Emotion recognition in schizophrenic and depressed inpatients. Journal of Clinical Psychology. 1986;48:411–417

PII: S0165-1781(03)00166-5

doi: 10.1016/S0165-1781(03)00166-5

Psychiatry Research
Volume 120, Issue 1 , Pages 13-27 , 30 August 2003

Article Tools

* Image Usage & Resolution